Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

RATIONALE The molecular mechanisms underlying acute exacerbations of idiopathic pulmonary fibrosis (IPF) are poorly understood. We studied the global gene expression signature of acute exacerbations of IPF. OBJECTIVES To understand the gene expression patterns of acute exacerbations of IPF. METHODS RNA was extracted from 23 stable IPF lungs, 8 IPF lungs with acute exacerbation (IPF-AEx), and 15 control lungs and used for hybridization on Agilent gene expression microarrays. Functional analysis of genes was performed with Spotfire and Genomica. Gene validations for MMP1, MMP7, AGER, DEFA1-3, COL1A2, and CCNA2 were performed by real-time quantitative reverse transcription-polymerase chain reaction. Immunohistochemistry and in situ terminal deoxynucleotidyltransferase dUTP nick end-labeling assays were performed on the same tissues used for the microarray. ELISA for alpha-defensins was performed on plasma from control subjects, patients with stable IPF, and patients with IPF-AEx. MEASUREMENTS AND MAIN RESULTS Gene expression patterns in IPF-AEx and IPF samples were similar for the genes that distinguish IPF from control lungs. Five hundred and seventy-nine genes were differentially expressed (false discovery rate < 5%) between stable IPF and IPF-AEx. Functional analysis of these genes did not indicate any evidence of an infectious or overwhelming inflammatory etiology. CCNA2 and alpha-defensins were among the most up-regulated genes. CCNA2 and alpha-defensin protein levels were also higher and localized to the epithelium of IPF-AEx, where widespread apoptosis was also detected. alpha-Defensin protein levels were increased in the peripheral blood of patients with IPF-AEx. CONCLUSIONS Our results indicate that IPF-AEx is characterized by enhanced epithelial injury and proliferation, as reflected by increases in CCNA2 and alpha-defensins and apoptosis of epithelium. The concomitant increase in alpha-defensins in the peripheral blood and lungs may suggest their use as biomarkers for this disorder.

[1]  K. Nagata,et al.  Alpha-defensin enhances expression of HSP47 and collagen-1 in human lung fibroblasts. , 2007, Life sciences.

[2]  B. Moore,et al.  Viruses as co-factors for the initiation or exacerbation of lung fibrosis , 2008, Fibrogenesis & tissue repair.

[3]  M. Yamaya,et al.  Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases , 2002, Thorax.

[4]  H. G. Boman,et al.  Peptide antibiotics and their role in innate immunity. , 1995, Annual review of immunology.

[5]  N. Kaminski,et al.  Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern , 2007, PloS one.

[6]  N. Kaminski,et al.  Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis , 2006, The Journal of experimental medicine.

[7]  H. Tomioka,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: Role of Chlamydophila pneumoniae infection , 2007, Respirology.

[8]  H. Collard,et al.  Acute exacerbations of idiopathic pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[9]  N. Kaminski,et al.  Lessons from Our Patients: Development of a Warm Autopsy Program , 2006, PLoS medicine.

[10]  A. Nicholson,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features , 2006, European Respiratory Journal.

[11]  P. Zabel,et al.  Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. , 1998, American journal of respiratory and critical care medicine.

[12]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[13]  R. Strawderman,et al.  Histopathologic variability in usual and nonspecific interstitial pneumonias. , 2001, American journal of respiratory and critical care medicine.

[14]  M. Akira,et al.  CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. , 1997, AJR. American journal of roentgenology.

[15]  P. O'Byrne,et al.  Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[16]  Naftali Kaminski,et al.  Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.

[17]  B. Afessa,et al.  Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. , 2002, American journal of respiratory and critical care medicine.

[18]  S. Tominaga,et al.  The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. , 2003, Chest.

[19]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[20]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[21]  M. Nakazato,et al.  Elevated BALF concentrations of α- and β-defensins in patients with pulmonary alveolar proteinosis , 2007 .

[22]  B. Moore,et al.  Exacerbation of Established Pulmonary Fibrosis in a Murine Model by Gammaherpesvirus at a Glance Commentary , 2022 .

[23]  Farshid N. Rouhani,et al.  Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[24]  N. Kaminski,et al.  A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.

[25]  Wei Wu,et al.  Comparison of normalization methods for CodeLink Bioarray data , 2005, BMC Bioinformatics.

[26]  F. Martinez,et al.  Recent advances in idiopathic pulmonary fibrosis. , 2007, Chest.

[27]  J. Myers,et al.  Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. , 2005, Chest.

[28]  P. Csermely,et al.  Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. , 1997, Molecular immunology.

[29]  Giovanni Parmigiani,et al.  Pre-processing Agilent microarray data , 2007, BMC Bioinformatics.

[30]  N. Siafakas,et al.  Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. , 2005, Chest.

[31]  M. Nakazato,et al.  Raised plasma concentrations of α-defensins in patients with idiopathic pulmonary fibrosis , 2002 .

[32]  M. Daha,et al.  Inhibition of activation of the classical pathway of complement by human neutrophil defensins. , 1998, Blood.

[33]  Naftali Kaminski,et al.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  David G. Morris,et al.  Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Nakazato,et al.  High concentrations of α-defensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome , 2004 .

[36]  R. Trisolini,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: report of a series , 2003, European Respiratory Journal.

[37]  Katsutoshi Nakayama,et al.  Anticoagulant therapy for idiopathic pulmonary fibrosis. , 2005, Chest.

[38]  Naftali Kaminski,et al.  MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008, PLoS medicine.

[39]  M. Selman,et al.  Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. , 2006, Proceedings of the American Thoracic Society.

[40]  Naftali Kaminski,et al.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. , 2006, American journal of respiratory and critical care medicine.

[41]  Tobias Meyer,et al.  Cyclin A2 Regulates Nuclear-Envelope Breakdown and the Nuclear Accumulation of Cyclin B1 , 2007, Current Biology.

[42]  R. Hyzy,et al.  Acute exacerbation of idiopathic pulmonary fibrosis. , 2007, Chest.

[43]  A. Nicholson,et al.  Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. , 2003, American journal of clinical pathology.

[44]  D. Koller,et al.  From signatures to models: understanding cancer using microarrays , 2005, Nature Genetics.

[45]  M. Nakazato,et al.  Differential effects of α- and β-defensin on cytokine production by cultured human bronchial epithelial cells , 2005 .

[46]  H. Collard,et al.  Classification and Natural History of the Idiopathic Interstitial Pneumonias Who Is at Risk of Ipf? What Causes Ipf? , 2022 .

[47]  Ivana V. Yang,et al.  Gene expression profiling of familial and sporadic interstitial pneumonia. , 2007, American journal of respiratory and critical care medicine.

[48]  Naftali Kaminski,et al.  Analysis of microarray experiments for pulmonary fibrosis. , 2005, Methods in molecular medicine.

[49]  M. Matthay,et al.  Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. , 2006, American journal of respiratory and critical care medicine.

[50]  K. Savik,et al.  Proteomic identification of human neutrophil alpha‐defensins in chronic lung allograft rejection , 2005, Proteomics.